Navigation Links
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Date:12/9/2013

RARITAN, N.J., Dec. 9, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events (AEs) that were predominantly Grade 1 or 2 in nature.

Efficacy data were also collected and showed that 71 percent (95% CI, 52.0-85.8) of patients treated with ibrutinib achieved an objective response (defined as a complete or partial response). Although estimates of progression-free survival (PFS) and overall survival (OS) were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.

"This early stage study in previously untreated patients suggests a positive effect with ibrutinib in CLL and SLL," said lead author Susan O'Brien, M.D., Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. "The results of this study are encouraging given the average age, overall health and unmet needs of the typical CLL population."

Primary Endpoint: Safety

Adverse events were predominantly Grade 1 or 2 in severity, with the most frequently (greater than or equal to 25 percent) reported being diarrhea (68 percent) which was often self-limited and resolved without discontinuation of treatment. Other common mild to moderate AEs that were reported included nausea (48 percent), fatigue (32 percent), hypertension (29 percent), peripheral edema (29 percent), dizziness (26 percent), dyspepsia (26 percent) and upper resp
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
2. New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
3. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
4. New Drug Application for Ibrutinib Submitted to the U.S. FDA
5. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
11. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Global Cardiac ... http://www.reportlinker.com/p0240523/Global-Cardiac-Monitoring-Systems-Market-2009-2013.html With advancements in technology, ... capabilities have been introduced in the Cardiac Monitoring ...
... 2011 Reportlinker.com announces that a new market ... Hepatitis A Preventive Vaccines - Pipeline ... http://www.reportlinker.com/p0453473/Hepatitis-A-Preventive-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Hepatitis A ... to 2017 SummaryGlobalData, the industry ...
Cached Medicine Technology:Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 2Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 3Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... science, "simple and accessible detection methods that can ... resolution of a single cell inside that population ... engineer Chang Lu. , In the Royal Society ... has announced that he and his coworkers have ... location of a protein ( Chem. Sci. , ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... of Science supports the protocol to reverse type 1 diabetes ... cells// from the spleen can add to the renewal of ... Hospital (MGH) showed the benefits of a procedure to turnaround ... from other institutions published in the March 24, 2006 issue ...
... reportedly swallowed tiny magnets that fell off toys had ... Product Safety Commission has// ordered a major recall of ... Mattel.,Mattel is an El Segundo-based toy manufacturer. ... complaints reporting that small magnets fell out of the ...
... stem cells increase insulin production in mice with type 2 ... diabetes, say Tulane University gene// therapy researchers. The article is ... Proceedings of the National Academy of Sciences. ... They have the potential to be used therapeutically because of ...
... Keio Medical Science Award from Keio University in Tokyo. ... at Yale, received the award in a ceremony and commemorative ... ,The award, made to researchers in recognition of their ... is the only prize of its kind awarded by a ...
... 2006 there are 57 million underweight children in India.// ... under the National Rural Health Mission (NRHM) to overcome ... Implementing the Integrated Management of Childhood Illnesses (IMNC) which ... childhood illnesses and malnutrition. ,2. Implementation ...
... Department for Health (DoH), UK has launched a new scheme ... to provide healthy nutrition to toddlers between 1// and 4 ... below 18. ,The Healthy Start scheme offers vouchers, ... supplements, milk or infant formula. Households with children under one ...
Cached Medicine News:Health News:New data from NIH lab confirms protocol to reverse type 1 diabetes in mice 2Health News:Yale Scientist Received Medical Science Prize From Keio University 2
Auto Refkeratomoeter...
... The InfusO.R. Pump is a ... aid in the administration of ... anesthetic procedures. It provides for ... muscle relaxants, and vasoactive drugs ...
Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: